Orciprenaline

Orciprenaline, also known as metaproterenol, is a bronchodilator used in the treatment of asthma.[1][2] Orciprenaline is a moderately selective β2 adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on α adrenergic receptors. The pharmacologic effects of β adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through β adrenergic receptors of intracellular adenylyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.

Orciprenaline
Clinical data
Other namesMetaproterenol (USAN US)
AHFS/Drugs.commonograph
MedlinePlusa682084
Pregnancy
category
  • AU: A
  • US: C (Risk not ruled out)
    Routes of
    administration    		Inhalation (MDI) and tablets
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Bioavailability3% if inhaled, 40% if taken orally
    MetabolismGastrointestinal and hepatic
    Elimination half-life6 hours
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.008.701
    Chemical and physical data
    FormulaC11H17NO3
    Molar mass211.258 g/mol g·mol−1
    3D model (JSmol)
    ChiralityRacemic mixture
    Solubility in water9.7 mg/mL (20 °C)
     NY (what is this?)  (verify)

    Possible side effects
    • tremor
    • nervousness
    • dizziness
    • weakness
    • headache
    • nausea
    • tachycardia
    Rare side effects that could be life-threatening
    • increased difficulty breathing
    • rapid or increased heart rate
    • irregular heartbeat
    • chest pain or discomfort

    Brand names
    • Alupent
    • Metaprel
    • Orcibest

    References
    1. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035–41. doi:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
    2. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic Acids Res. 36 (Database issue): D901–6. doi:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.